Cancer drug resistance: A brief overview from a genetic viewpoint
J Rueff, AS Rodrigues - Cancer Drug Resistance: Overviews and Methods, 2016 - Springer
Cancer drug resistance leading to therapeutic failure in the treatment of many cancers
encompasses various mechanisms and may be intrinsic relying on the patient's genetic …
encompasses various mechanisms and may be intrinsic relying on the patient's genetic …
The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so
A recent paper in this journal sought to counter evidence for the role of transport proteins in
effecting drug uptake into cells, and questions that transporters can recognize drug …
effecting drug uptake into cells, and questions that transporters can recognize drug …
Pharmacogenomics of impaired tyrosine kinase inhibitor response: lessons learned from chronic myelogenous leukemia
M Kaehler, I Cascorbi - Frontiers in Pharmacology, 2021 - frontiersin.org
The use of small molecules became one key cornerstone of targeted anti-cancer therapy.
Among them, tyrosine kinase inhibitors (TKIs) are especially important, as they were the first …
Among them, tyrosine kinase inhibitors (TKIs) are especially important, as they were the first …
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation
AT Nies, E Schaeffeler, M Schwab - Pharmacology & Therapeutics, 2022 - Elsevier
Organic cation transporters (OCT), organic anion transporting polypeptides (OATP) and
organic anion transporters (OAT) from the solute carrier (SLC) family play an essential role …
organic anion transporters (OAT) from the solute carrier (SLC) family play an essential role …
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib
The efflux transporters adenosine triphosphate (ATP)‐binding cassette (ABC) B1 and
ABCG2 have been demonstrated to interact with the tyrosine kinase inhibitors (TKIs) …
ABCG2 have been demonstrated to interact with the tyrosine kinase inhibitors (TKIs) …
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
Tyrosine kinase inhibitor (TKI) therapy results in excellent responses in the majority of
patients with chronic myeloid leukaemia. First-line imatinib treatment, with selective …
patients with chronic myeloid leukaemia. First-line imatinib treatment, with selective …
The roles of microRNAs in cancer multidrug resistance
L Pavlíková, M Šereš, A Breier, Z Sulová - Cancers, 2022 - mdpi.com
Simple Summary The resistance of neoplastic cells to multiple drugs is a serious problem in
cancer chemotherapy. The molecular causes of multidrug resistance in cancer are largely …
cancer chemotherapy. The molecular causes of multidrug resistance in cancer are largely …
A longitudinal study of ABC transporter expression in canine multicentric lymphoma
Canine lymphoma is typically treated with a doxorubicin-based multidrug chemotherapy
protocol. Although this is often initially successful, tumour recurrence is common and …
protocol. Although this is often initially successful, tumour recurrence is common and …
Importance of ABCC1 for cancer therapy and prognosis
T Kunicka, P Souček - Drug metabolism reviews, 2014 - Taylor & Francis
Multidrug resistance presents one of the most important causes of cancer treatment failure.
Numerous in vitro and in vivo data have made it clear that multidrug resistance is frequently …
Numerous in vitro and in vivo data have made it clear that multidrug resistance is frequently …
[HTML][HTML] Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma
Y Li, C Zhao, Z Yu, J Chen, X She, P Li, C Liu… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Osteosarcoma (OS) is the most common primary bone malignancy with a poor prognosis for
all races and both sexes. In this study, we found that miR-381 is a positive prognosis factor …
all races and both sexes. In this study, we found that miR-381 is a positive prognosis factor …